Vir Biotechnology licenses CHD combination to Norgine for Europe, Australia, New Zealand
Vir Biotechnology granted Norgine Pharma UK Limited an exclusive license for commercial rights to its tobevibart and elebsiran combination for chronic hepatitis delta in Europe, Australia and New Zealand. Vir will receive an initial reimbursement of EUR 55 million, is eligible for up to EUR 495 million in milestones, and will earn royalties on net sales in that territory, while the companies share ECLIPSE trial costs. The company says the agreement extends its current cash runway into the fourth quarter of 2027.
Key points
- Initial reimbursement payment of EUR 55 million to Vir, with closing for certain non-US jurisdictions subject to regulatory approval
- Eligible for up to EUR 495 million in clinical, regulatory and sales milestones, plus tiered mid-teen to high-twenties percent royalties on net sales in the licensed territory
- Norgine to contribute approximately 25% of go-forward external costs for the ECLIPSE 1, 2 and 3 trials
- Vir retains commercial rights in the United States and other markets outside the Greater China Territory; company expects cash runway into Q4 2027
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 16, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.